Abstract
The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Current Drug Targets
Title: Natural History of Ulcerative Colitis: Current Knowledge
Volume: 12 Issue: 10
Author(s): Lajos Sandor Kiss and Peter Laszlo Lakatos
Affiliation:
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Abstract: The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Export Options
About this article
Cite this article as:
Sandor Kiss Lajos and Laszlo Lakatos Peter, Natural History of Ulcerative Colitis: Current Knowledge, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818117
DOI https://dx.doi.org/10.2174/138945011796818117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Do We Have Another Option to Treat Bleeding Hemorrhoids? The Emborrhoid Technique: Experience in 16 Patients
Reviews on Recent Clinical Trials Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
Current Drug Metabolism The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network
Letters in Drug Design & Discovery Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer
Current Medical Imaging Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Virtual Screening of Potential Anti-fatigue Mechanism of Polygonati Rhizoma Based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Editorial [ Hot Topic:Biology in Anticancer Treatment (Guest Editor: Bruno Vincenzi)]
Current Cancer Drug Targets From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Proteasome Inhibitors in Cancer Therapy
Current Drug Targets